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Abstract
Background: The Rasd1 protein is a dexamethasone induced monomeric Ras-like G protein that oscillates in the
suprachiasmatic nucleus (SCN). Previous studies have shown that Rasd1 modulates multiple signaling cascades.
However, it is still unclear exactly how Rasd1 carries out its function. Studying protein-protein interactions involving
Rasd1 may provide insights into its biological functions in different contexts.
Results: To further explore the molecular function of Rasd1, we performed a yeast two-hybrid screen and
identified Ear2, a negative regulator of renin transcription, as an interaction partner of Rasd1. We validated the
interaction in vitro and in transfected COS-7 cells. We further confirmed the interaction of endogenous Rasd1 and
Ear2 from HEK293T cell and mouse brain extract. Rasd1 inhibited transcriptional repression by Ear2 on a renin
promoter-luciferase reporter construct both in the presence and absence of all-trans-retinoic acid. Moreover, real-
time RT-PCR showed upregulation of endogenous renin transcription in As4.1 cells over-expressing Rasd1. We
demonstrated that the ligand binding domain of Ear2 is required for physical and functional interaction between
the two proteins. In addition, we demonstrated that shRNA-mediated knockdown of Rasd1 results in further
repression of Ear2-mediated renin transcription, whereas induction of Rasd1 by dexamethasone counteracts the
effects of shRNA-mediated Rasd1 knockdown. Finally, our study showed that Rasd1 missense mutations not only
attenuate their physical interaction with Ear2 but also abolish their ability to counteract repression of renin
transcription mediated by Ear2.
Conclusions: Our study provides evidence for physical and functional interactions between Rasd1 and Ear2. The
results suggest that their interactions are involved in renin transcriptional regulation. These findings not only reveal
a novel role for Rasd1-medated signaling but also provide the basis for potential intervention of renin expression.
Background
The renin-angiotensin system plays a major physiological
role in the control of blood pressure, fluid volume and
electrolyte balance. A functional renin-angiotensin sys-
tem is also essential for the normal development of the
mammalian renal system [1]. Renin, an aspartyl protease,
is the rate-limiting enzyme in the renin-angiotensin enzy-
matic cascade which leads to the production of angioten-
sin II (Ang II), a vasoactive peptide and major effector
molecule in the renin-angiotensin system [2,3]. Renin
gene expression is largely regulated at the transcriptional
level, although post transcriptional regulation has also
been reported [4,5]. A potent classical transcriptional
enhancer was identified ~2.6 kb upstream of the mouse
renin gene, and this enhancer is homologous to a
sequence ~12 kb upstream of the human renin gene
[6-8]. The transcriptional enhancer contains several tran-
scription factor binding sites that have both excitatory
and inhibitory regulatory functions [9-12].
One protein that has been identified to bind to and
regulate the renin enhancer is Ear2 [13]. It was deter-
mined that Ear2 negatively regulates renin expression by
competing with retinoic acid receptor/ retinoid X recep-
tor (RAR/RXR) for binding to the retinoic acid response
elements (RARE) on the renin enhancer [13]. Ear2 is an
orphan nuclear hormone receptor that belongs to the
chicken ovalbumin upstream promoter-transcription
factors (COUP-TF) gene family [14]. COUP-TFs have
been shown to bind to a number of variable direct and
indirect repeats with different spacings between the
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repeats [15] to affect a large plethora of genes [16-19].
COUP-TFs have been proposed to inhibit transactivation
of other nuclear receptors through multiple mechanisms,
including competitively binding to regulatory elements,
competitively binding to RXR, mediating active repres-
sion via direct binding to regulatory elements, and med-
iating transrepression of another nuclear receptor
without binding to DNA itself [14,20-22]. Nuclear hor-
mone receptors have the ability to bind directly to DNA
and regulate the expression of specific target genes;
therefore, they are extremely crucial to the development,
homeostasis and metabolism of an organism [16,20,21,
23-25]. Ear2 is expressed in tissues of all major systems,
and its expression has been implicated in the regulation
of gene expression for normal embryo development
[26,27]. Ear2 knockout mice are viable and fertile, but
they possess circadian and nociception defects and
abnormal locus coeruleus (LC) development [25].
Using a yeast two-hybrid system, we identified Ear2 as
an interacting protein of Rasd1. Rasd1 is a G-protein
that belongs to the RAS superfamily of small GTPases.
It was first discovered as a dexamethasone-inducible
gene in the AtT-20 pituitary cell line [28]. Rasd1 is an
oscillating gene specific to the suprachiasmatic nucleus
(SCN) [29]. Rasd1 modulates several signaling cascades
and has several known functions. It interacts with
neuronal nitric oxide synthase via CAPON to enhance
physiological nitric oxide signaling [30]. Rasd1 is also
crucial in the regulation of the responsiveness of the
circadian clock to external stimuli [31]. In this study, we
demonstrate that the interaction between Rasd1 and
Ear2 regulates renin transcription. Our findings reveal a
novel regulatory role of Rasd1 and a novel regulatory
mechanism for Ear2-mediated renin transcription.
Results
Identification of Ear2 as a Rasd1 interacting protein- To
identify the proteins that are associated with Rasd1, we
conducted a yeast two-hybrid screen. A mouse brain
cDNA library was screened against full length Rasd1. All
surviving colonies after nutritional selection were
screened for LacZ expression using b-galactosidase.
Table 1 lists the proteins that were identified. Ear2 is
the protein for which the highest number of indepen-
dent clones was obtained, with a total of three clones
identified. To confirm the specificity of interaction
between Rasd1 and Ear2, a separate yeast two-hybrid
analysis was performed by mating yeast containing the
Ear2 cDNA plasmid with yeast that already carried
Rasd1. This was followed by nutritional selection and
b-galactosidase assay. Ear2 again showed positive inter-
actions with Rasd1 (not shown).
Rasd1 and Ear2 interact in vitro and in living cells-
To confirm the specificity of biochemical interaction
between Rasd1 and Ear2, we conducted an in vitro bind-
ing study utilizing transfected COS-7 cells. GST-Ear2
was immobilized on GSH-linked beads. The GST fusion
protein containing full-length Ear2 interacted with HA-
tagged full-length Rasd1 from the lysate of transfected
COS-7 cells (Figure 1A, lane 1), whereas GST itself
showed no such interaction (Figure 1A, lane 2).
To test whether Rasd1 and Ear2 interact in intact
mammalian cells, we performed co-transfection and
co-precipitation experiments. pHisHA-Rasd1 was
co-transfected together with pGST-Ear2 into COS-7
cells. As a control, pHisHA-Rasd1 was co-trans-
fected with pxJGST into COS-7 cells. GST-Ear2 or
GST from transfected COS-7 cell lysate was
immobilized on GSH-linked magnetic particles. Pre-
cipitation of GST-Ear2 resulted in the co-precipita-
tion of HisHA-Rasd1 (Figure 1B, lane 1), whereas
precipitation of GST-tag alone did not co-precipitate
HisHA-Rasd1 (Figure 1B, lane 2). This demonstrates
that Rasd1 and Ear2 form a physiological complex in cul-
tured cells. Additionally, a co-immunoprecipitation assay
was carried out using lysate derived from COS-7 co-trans-
fected with pHisHA-Rasd1 and pGST-Ear2. As a control,
experiments were also conducted using lysate derived
from COS-7 cells co-transfected with pHisHA-Rasd1 and
pxJGST. Immunoprecipitation of GST-Ear2 with
anti-GST antibody resulted in the co-precipitation of
HisHA-Rasd1 (Figure 1C, lane 1). There was no non-spe-
cific interaction between GST tag and HisHA-Rasd1
(Figure 1C, lane 2).
Interaction of endogenous Rasd1 and Ear2 was identi-
fied in HEK293T cells and the mouse brain- The exis-
tence of endogenous Rasd1-Ear2 complexes was further






1 Cenpb Mus musculus centromere protein B NM_007682.2
2 Gnb1 Mus musculus guanine nucleotide
binding protein, beta 1
NM_008142.3
3 Nr2f6 Mus musculus nuclear receptor
subfamily 2, group F, member 6
NM_010150.2
4 Plscr1 Mus musculus phospholipid
scramblase 1
NM_011636.2
5 Sh3gl2 Mus musculus SH3-domain GRB2-like 2 NM_019535.2
6 Supt16 h Mus musculus suppressor of Ty 16
homolog
NM_033618.2
7 Trp53bp2 Mus musculus transformation related
protein 53 binding protein 2
NM_173378.2
8 Ywhah Mus musculus tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, eta
polypeptide
NM_011738.1
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demonstrated by co-immunoprecipitation of the protein
complex from both HEK293T cells and mouse brain.
Immunoprecipitation of endogenous Ear2 resulted in
the co-immunoprecipitation of Rasd1 (Figure 1D, lane 1
and Figure 1E, lane 1), but immunoprecipitation
performed with a non-relevant goat polyclonal IgG anti-
body did not co-immunoprecipitate Rasd1 (Figure 1D,
lane 2 and Figure 1E, lane 2). These experiments con-
firm the specificity of the endogenous interaction
between Rasd1 and Ear2.
Figure 1 Rasd1 and Ear2 interact in vitro and in living cells. (A) In vitro binding of GST-Ear2 and HisHA-Rasd1. COS-7 cells were transfected
with plasmids expressing the indicated constructs. Cell lysates containing HisHA-Rasd1 was incubated with immobilized GST-Ear2 or GST, and
specifically bound HisHA-Rasd1 was eluted by heating at 95°C for 10 minutes, and detected by Western blotting with Anti-HA antibody. (B)
HisHA-Rasd1 and GST-Ear2 interact in intact mammalian cells. pHisHA-Rasd1 was co-transfected with plasmids expressing either GST-Ear2 or GST
into COS-7 cells. GST and GST-Ear2 were captured from the cell lysates by GSH-linked beads and HisHA-Rasd1 bound to the beads were
detected as above. (C) COS-7 cells were co-transfected with plasmids expressing HisHA-Rasd1 and GST-Ear2 or GST. Immunoprecipitations were
performed with anti-GST antibody. Co-immunoprecipitated HisHA-Rasd1 was detected by Anti-HA antibody. (D and E) Rasd1 and Ear2 form a
physiological complex in living cells. Endogenous Rasd1-Ear2 complexes were detected by immunoprecipitating Ear2 from HEK293T cell lysates
(D) or mouse brain lysates (E) with goat polyclonal IgG anti-Ear2 antibody, and probing for Rasd1 (D and E, lanes 1). A non-relevant goat
polyclonal IgG antibody was used as a negative control (D and E, lanes 2). IP and IB denote immunoprecipitation and immunoblot, respectively.
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Rasd1 alleviates Ear2-mediated repression of renin
transcription- Ear2 binds to the RARE on the renin
enhancer and negatively regulates renin gene transcrip-
tion [13]. The most important regulatory regions of the
mouse renin gene reside in 4.1 kb of the renin 5’ flank-
ing sequence [6,32]. To explore the possibility that
Rasd1 modulates Ear2-mediated transrepression of renin
expression, we cloned the 4.1 kb renin promoter and
enhancer into the promoterless, enhancerless luciferase
pGL3-Basic vector (p4.1-Luc). COS-7 cells were trans-
fected with pGL3-basic or p4.1-Luc or p4.1-Luc and
pGST-Ear2. We first validated that Ear2 acts as a nega-
tive regulator on renin gene transcription [13] in COS-7
cells (Figure 2A). We then proceeded to test if Rasd1
was able to modulate renin transcription in the presence
of Ear2. Our results show that Rasd1 alleviates the Ear2-
mediated transcriptional repression of renin promoter
activity in a dosage-dependent manner (Figure 2B). It
has also been reported that Ear2 is able to downregulate
retinoic acid-induced renin transcription [13]. We vali-
dated this result (Figure 2C) and tested if Rasd1 was
able to alleviate Ear2-mediated transcriptional repression
of retinoic acid-induced renin expression. Our results
suggest that Rasd1 is able to alleviate Ear2-mediated
transcriptional repression of retinoic acid-induced renin
promoter activity in a dosage dependent manner (Figure
2D and 2E).
Rasd1 modulates endogenous renin gene expression by
interacting with Ear2- We also investigated the effects
of Ear2 and Rasd1 on endogenous renin gene expression
in As4.1 cells. As4.1 cells express endogenous renin, as
well as Rasd1 and Ear2. Real-time RT-PCR showed that
renin mRNA levels were lower in the cells over-expres-
sing Ear2. Renin mRNA in As4.1 cells over-expressing
Ear2 were reduced to about 48% of the control
(Figure 3A, compare bars I and II). When pHisHA-
Rasd1 was co-transfected with pGST-Ear2 into As4.1
cells, the repression of renin transcription by Ear2 was
inhibited (Figure 3A, compare bars II and III). Renin
mRNA levels increased to almost twice the amount of
control when Rasd1 was over-expressed (Figure 3A,
compare bars I and III). This spike in renin gene expres-
sion when Rasd1 was over-expressed could be attributed
to the presence of abundant Rasd1, which might have
counteracted the repression of renin transcription by
both endogenous and transfected Ear2.
We proceeded to test if alteration of Rasd1 levels in
As4.1 cells is capable of modulating Ear2-mediated
repression of renin transcription. As4.1 cells are known
to express high level of renin [33]. We first demon-
strated that Rasd1 shRNA, but not control shRNA,
effectively knocked down endogenous expression of
Rasd1 mRNA (Figure 3B, upper panel) and protein (Fig-
ure 3B, lower panel) in As4.1 cells. Quantifications with
the densitometer indicated that protein levels were
knocked down by more than 48%. In addition, we
demonstrated that shRNA-mediated knockdown of
Rasd1 results in a further repression of Ear2-mediated
renin transcription (Figure 3C, compare bars V and VI).
Because dexamethasone is known to induce Rasd1
expression [28], we examined whether dexamethasone
could counteract the effects of shRNA-mediated Rasd1
knockdown. In the presence of dexamethasone, Ear2-
repressed renin transcription was alleviated (Figure 3C,
compare bars V and VII). This resembled the results we
observed from Rasd1 over-expression (Figure 3C, com-
pare bars III and IV). Treatment with dexamethasone
counteracted the effects of Rasd1 shRNA on the Ear2-
mediated repression of renin transcription (Figure 3C,
compare bars VI and VIII); however, renin transcription
levels were restored to lower levels than that of treat-
ment with dexamethasone alone (Figure 3C, bar VII).
Our experiments suggest that transcriptional repression
of renin by Ear2 can be modulated by alternating the
level of Rasd1 in As4.1 cells.
Ear2 interacts with Rasd1 via its ligand binding
domain- Ear2 is a 390 amino acid nuclear hormone
receptor and is known to contain several domains,
including an activator function I site (residues 1-53), a
DNA-binding domain (residues 54-130), a linker region
(residues 131-193) and a ligand binding domain (resi-
dues 194-376). To elucidate how Rasd1 interacts with
Ear2, we generated six GST-Ear2 truncated constructs
(Figure 4A) and used them to carry out co-precipitation
assays against full-length HisHA-Rasd1. We found that
only full-length Ear2 (Figure 4A, Ear2-FL) and Ear2
truncated constructs that contain the ligand binding
domain (Figure 4A, Ear2-C54, Ear2-C131 and Ear2-
C194) co-precipitated with HisHA-Rasd1 (Figure 4B,
lane 1 and lanes 5-7). This indicates that the C-terminus
ligand binding domain, containing amino acids 194-390,
is required for the binding of Ear2 to Rasd1.
Ear2 ligand binding domain is required for Rasd1 to
alleviate Ear2-mediated repression of renin transcrip-
tion- To further investigate the binding of Ear2 on the
renin enhancer [13], we performed luciferase assay using
the six truncated constructs of Ear2. Ear2 deletion con-
structs devoid of the DNA binding domain markedly
lost their ability to repress renin transcription (Figure
4C, bars with Ear2-N53, Ear2-C131 and Ear2-C194).
This result is in accordance with previous report which
shows that Ear2 with a mutated DNA binding domain is
unable to bind to the RARE and ineffective in inhibiting
the activity of the renin promoter [13].
When Rasd1 was added, we observed that Rasd1 alle-
viated Ear2-mediated transcriptional repression of renin
promoter activity only in Ear2 constructs with intact
DNA and ligand binding domains (Figure 4C, bars with
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Figure 2 Rasd1 counteracts repression of renin transcription by Ear2. (A) Luciferase assay showed that transcription of renin is repressed by
Ear2. COS-7 cells were transfected with pGL3-basic (2.0 μg) or p4.1-Luc (2.0 μg) or p4.1-Luc (2.0 μg) and pGST-Ear2 (1.5 μg), and with pSV-b-gal
(0.5 μg). p4.1-Luc construct was generated by cloning the 4.1 kb renin promoter into pGL3-basic vector. Relative luciferase activity was
normalized against b-gal activity. (B) Rasd1 alleviates Ear2-mediated repression of renin transcription in a dosage dependent manner. COS-7 cells
were transfected with a constant amount of p4.1-Luc (2.0 μg), pSV-b-gal (0.5 μg) and pGST-Ear2 (1.5 μg), and with an increasing amount of
pHisHA-Rasd1 (0.1, 0.2, 0.5, 1.0 and 1.5 μg). (C) Ear2 attenuates the renin promoter activity induced by retinoic acid in a dosage dependent
manner. COS-7 cells were transfected with a constant amount of p4.1-Luc (2.0 μg), pSV-b-gal (0.5 μg) and pHisHA-Rasd1 (1.5 μg), and with an
increasing amount of pGST-Ear2 (0.5, 1.0 and 1.5 μg). Renin transcription was induced by all-trans retinoic acid 24 hours post transfection. (D and
E) Rasd1 alleviates Ear2-mediated repression of retinoic acid induced renin transcription in a dosage dependent manner. The effect of Rasd1 and
Ear2 on retinoic induced renin transcription was tested by measuring the luciferase activity in varying amounts of either Ear2 (D) or Rasd1 (E).
The amounts of pGST-Ear2 transfected in D were 0.5, 1.0 and 1.5 μg; the amounts of pHisHA-Rasd1 transfected in E were 0.2, 0.5, 1.0 and 2.0 μg.
* and ** denotes p < 0.05 and p < 0.01 respectively. (A-E) In all luciferase assays, controls were transfected with pGL3-basic (2.0 μg), pSV-b-gal
(0.5 μg) and appropriate amounts of the respective carrier vectors.
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Figure 3 Transcriptional repression of renin by Ear2 can be modulated by alternating the endogenous level of Rasd1. (A) Real-time
RT-PCR was conducted to determine level of endogenous renin transcription when Rasd1 was overexpressed. As4.1 cells were transiently
transfected with pxJGST (2.0 μg) and pcDNA4.0 (3.5 μg) (bar I), or pGST-Ear2 (2.0 μg) and pcDNA4.0 (3.5 μg) (bar II), or pHisHA-Rasd1 (3.5 μg) and
pcDNA4.0 (3.5 μg) (bar III). Representative immunoblots demonstrated Ear2 and Rasd1 transgene expression 48 hours after transfection (lower
panels). (B) Semi-quantitative RT-PCR showed Rasd1 knockdown in the As4.1 cells. As4.1 cells were transfected with Rasd1 shRNA or control
shRNA (4.0 μg). Cells were selected with puromycin 24 hours post transfection and harvested 48 hours post transfection. The cDNA amplified
were run on a 1.5% agarose gel with G3PDH as an internal control (upper panels). A representative immunoblot demonstrated endogenous
Rasd1 protein knockdown by Rasd1 shRNA (lower panel). Proteins were detected with anti-Rasd1 and anti-actin antibodies. Quantification of the
immunoblots by densitometer revealed that Rasd1 protein levels, normalized against actin protein levels, were knocked down by more than 48%
(lower panels). (C) Luciferase study showed that dexamethasone treatment counteracts the effect of Rasd1 shRNA knockdown. As4.1 cells were
transfected with p4.1-Luc (2.0 μg), pGST-Ear2 (1.5 μg), pHisHA-Rasd1 (1.5 μg), Rasd1 shRNA or control shRNA as indicated (4.0 μg), together with
pSV-b-gal (0.5 μg). Controls were transfected with pGL3-basic (2.0 μg), pSV-b-gal (0.5 μg) and appropriate amounts of the respective carrier
vectors. Cell were selected with puromycin (2 μg/ml) and induced by dexamethasone (100 nM) 24 hours after transfection. Cells were harvested
and analyzed for luciferase activity 48 hours after transfection. Relative luciferase activity was normalized against b-gal activity. * and ** denotes
p < 0.05 and p < 0.01, respectively.
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Figure 4 Ear2 ligand binding domain interacts with Rasd1. (A) Schematic diagram showing the truncated constructs of Ear2. Ear2 contains 4
main domains: an activator function I site, a DNA binding domain, a zinc finger domain and a ligand binding domain. Full length (FL) Ear2 has 390
amino acids and each of the six truncated Ear2 constructs is represented by their amino acid numbers on the left. (B) Immunoblot analysis showed
that Rasd1 binds to Ear2 ligand binding domain. COS-7 cells were co-transfected with pHisHA-Rasd1 and the indicated pGST-Ear2 constructs. HisHA-
Rasd1 from the cell lysates was immobilized on Ni-NTA beads and GST-Ear2 constructs bound to the complexes were eluted by heating at 95°C for 10
minutes, and detected by immunoblotting with anti-GST (lanes 1 and 5-7). GST-Ear2 constructs not co-precipitated with HisHA-Rasd1 were detected in
the flow-through (lanes 2-4 and 8). (C) Luciferase study showed that Ear2 ligand binding domain and DNA binding domain are required for interacting
with Rasd1 to modulate renin transcription. COS-7 cells were transfected with p4.1-Luc (2.0 μg), pGST-Ear2 (1.5 μg) or plasmids expressing Ear2
truncated constructs and pHisHA-Rasd1 (1.5 μg) as indicated, together with pSV-b-gal (0.5 μg). Total DNA transfected was held constant with the
respective carrier vector plasmids. Controls are transfected with pGL3-basic (2.0 μg), pSV-b-gal (0.5 μg) and appropriate amounts of the respective
carrier vectors. Relative luciferase activity was normalized against b-gal activity. Ear2 constructs that were missing their DNA binding domains (Ear2-
N53, Ear2-C131, Ear2-C194) did not significantly repress renin transcription. Rasd1 alleviated Ear2-repressed renin transcription only if Ear2 ligand
binding domain is present (Ear2-FL, Ear2-C54). * denotes p < 0.05.
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Ear2-FL and Ear2-C54). This further confirms our
previous observations that Rasd1 interacts with the ligand
binding domain of Ear2. It also shows that the specific
binding of Rasd1 to Ear2 is essential for Rasd1 to counter-
act Ear2-mediated transrepression of renin promoter. In
addition, it was observed that the activator function I
domain (Figure 4A, Ear2-N53) of Ear2 was not required
for its repression of renin promoter activity. Deletion of
the activator function I domain has no influence on either
the Ear2-mediated repression or the Rasd1-mediated
alleviation of renin promoter activity (Figure 4C, lanes
with Ear2-FL and Ear2-C54).
Rasd1 and Ear2 colocalize in the nuclei - Rasd1 and
Ear2 must both be physically present in the same cel-
lular compartment to form a physiological complex.
We therefore decided to examine the localization of
Rasd1 and Ear2 in transfected COS-7 cells. When
transfected alone, HisHA-Rasd1 was expressed in both
the cytoplasm and the nucleus (Figure 5, A1-3), while
GST-Ear2 was present mainly in the nucleus (Figure 5,
B1-3). When GST-Ear2 and HisHA-Rasd1 were co-
expressed, it was observed that HisHA-Rasd1 and
GST-Ear2 colocalized in both the cytoplasm and the
nucleus (Figure 5, C1-4). It is interesting to note that
the amount of GST-Ear2 present in the cytoplasm was
dramatically increased in the presence of HisHA-Rasd1
(compare Figure 5, B1 with C2); there was no notice-
able change in the distribution of HisHA-Rasd1 in the
presence or absence of GST-Ear2 (compare Figure 5,
A1 with C1).
Missense mutations in Rasd1 abolished its physical and
functional interaction with Ear2- Rasd1 is a brain-
enriched G protein that belongs to the RAS superfamily
[34]. RAS superfamily members consists of GTPases with
high conservation in sequence and structural organiza-
tion, especially within their GTP binding pockets -G1,
G3, G4 and G5 boxes [34]. Most RAS subfamily proteins
also possess a C-terminus CAAX box, which undergoes
post-translational isoprenylation and regulates the sub-
cellular localization and function of the proteins [35]. To
investigate whether GTPase activity, GDP-GTP exchange
by GEF and post-translational isoprenylation of Rasd1
are required for its alleviation of Ear2-mediated repres-
sion of renin transcription, we generated four Rasd1
mutants- Rasd1[A178V], Rasd1[G81A], Rasd1[T38N]
and Rasd1[ΔCAAX]. Rasd1[A178V] [36] contains a single
nucleotide mutation in the G5 domain, disrupting its
guanyl nucleotide binding pocket. Rasd1 [A178V]
behaves functionally as a constitutively active signal
transducer. Rasd1[G81A] possesses a point mutation that
lies on a highly conserved glycine residue in the G3 box
[37]. In human HRAS, the corresponding G60A mutation
drastically reduces its GTPase activity [38]. Rasd1[T38N]
contains a mutation in the G1 box, corresponding to
human RAS[S17N]. Human HRAS[S17N] binds guanine
nucleotide exchange factors (GEFs) but does not catalyze
the release of GDP, thus effectively blocking the activa-
tion of RAS [39,40]. To explore the potential role of
isoprenylation in the functional properties of Rasd1, we
generated Rasd1[ΔCAAX]. This mutant contains a pre-
mature termination codon that gives rise to a truncated
Rasd1 devoid of the CAAX box.
The Rasd1 mutant constructs were co-transfected with
Ear2 and their cellular localization was examined. Rasd1
[A178V] and Rasd1[T38N] exhibited a similar distribu-
tion to that of wild type Rasd1 and were present in both
the nucleus and cytoplasm (Figure 5, A1, D1 and F1).
Rasd1[G81A] and Rasd1[ΔCAAX] were located only in
the nucleus (Figure 5, E1 and G1). When co-expressed
with Ear2, the amount of Ear2 present in the cytoplasm
was visibly increased in the presence of Rasd1[A178V]
(compare Figure 5, B1 and D2). On the other hand,
Rasd1[G81A], Rasd1[T38N] and Rasd1[ΔCAAX] did not
alter the distribution of Ear2. Ear2 was still mostly
located in the nucleus in the presence of these Rasd1
mutants (Figure 5, E2, F2, and G2).
We proceeded to perform luciferase assays to investigate
the effect of the expression of wild-type versus various
mutant Rasd1 proteins on Ear2-mediated renin promoter
activity in three cell lines, including COS-7 (monkey kid-
ney fibroblast cell line), As 4.1 (mouse juxtaglomerular cell
line) and Neuro2a (mouse neuroblastoma cell line). Both
As4.1 and Neuro2a cells are known to endogenously
express renin [33,41], whereas no endogenous expression
of renin is observed in COS-7cells [12]. In agreement with
this, the 4.1-Luc reporter construct exhibited an eleven
fold and four fold higher luciferase reporter activity in
As4.1 and Neuro2a cells, respectively, than in COS-7 cells
(compare Figure 6 bars: BII and AII; CII and AII). Lucifer-
ase reporter assay showed that over-expression of Ear2
suppressed renin promoter activity in all three cell lines
(compare Figure 6 bars: AII and AIII; BII and BIII; CII and
CIII) and over-expression of Rasd1 alleviated Ear2-
mediated down regulation of the renin promoter (compare
Figure 6 bars: AIII and AIV; BIII and BIV; CIII and CIV).
Likewise, Rasd1[A178V], a constitutively active mutant,
alleviated Ear2-mediated down-regulation of the renin
promoter in a magnitude similar to that of wild-type
Rasd1 (Figure 6A, compare bars: AIII and AIV; BIII and
BIV; CIII and CIV). In contrast, Rasd1[G81A], Rasd1
[T38N] and Rasd1[ΔCAAX] did not significantly alleviate
Ear2-mediated down-regulation of renin transcription
(Figure 6A, compare bars III, IV and VI-VIII), thus indi-
cating that the GTP hydrolysis activity of Rasd1, GDP-
GTP exchange by GEF and isoprenylation of Rasd1 are
required for counteracting Ear2-mediated repression of
renin transcription. To investigate whether Rasd1[A178V],
Rasd1[G81A], Rasd1[T38N] and Rasd1[ΔCAAX]
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Figure 5 Effects of wild-type and Rasd1 mutants on nuclear-cytoplasmic distribution of Ear2. (A-G) Immunofluorescence staining of COS-
7 cells transfected with pHisHA-Rasd1 (A1-3) or pGST-Ear2 (B1-3) or pHisHA-Rasd1 (wild type or mutants) + pGST-Ear2 (C1 to G4). HisHARasd1
(wild type or mutants) were detected with anti-HA antibody and visualized with AlexaFluor 568 (red); GST-Ear2 was labeled with anti-GST
AlexaFluor 488 (green); nucleus was labeled with 4’,6-diamidino-2-phenylindole (DAPI) (blue). Confocal imaging showed that HisHA-Rasd1 is
present in both the nucleus and cytoplasm (A1-3). GST-Ear2 is located mainly in the nucleus (B1-3), but when co-transfected together with
HisHA-Rasd1, GST-Ear2 is detected in both the nucleus and cytoplasm (C2).
Tan et al. BMC Molecular Biology 2011, 12:4
http://www.biomedcentral.com/1471-2199/12/4
Page 9 of 17
Figure 6 (A-C) Effects of wild-type and Rasd1 mutants on Ear2-mediated renin transcription. Luciferase studies showed that: A, COS-7; B,
As4.1; C, Neuro2a. Rasd1[A178V] mutant alleviated Ear2-mediated repression of renin transcription in a magnitude similar to wild-type Rasd1
(compare bars IV and V), whereas Rasd1[G81A], Rasd1[T38N] and Rasd1[ΔCAAX] did not significantly alleviate Ear2-mediated repression of renin
transcription (bars VI-VIII). (A, B and C, lower panels) Western blots showed similar expression efficiency of proteins. In all blots, expression of
actin is shown as a protein loading control. * and ** denotes p < 0.05 and p < 0.01, respectively. (D) Co-precipitation followed by immunoblot
showed that Rasd1[G81A], Rasd1[T38N] and Rasd1[ΔCAAX] mutations interfere with their ability to interact with Ear2. COS-7 cells were co-
transfected with pGST-Ear2 and the respective Rasd1 construct expressing plasmids or the empty vector. Precipitation of GST-Ear2 with GSH-
linked magnetic beads co-precipitated with Rasd1 proteins expressed from each construct (panel a, lanes I-V). However, the amount of HAHis-
Rasd1[G81A], HAHis-Rasd1[T38N] and HAHisRasd1[ΔCAAX] co-precipitated were significantly less than that of HAHis-Rasd1 and HAHis-Rasd1
[A178V] (compare panel a, lanes I and II with lanes III-V). Similarly, co-precipitation assays using magnetic Ni-NTA beads revealed that the amount
of GST-Ear2 co-precipitated with HAHis-Rasd1[G81A], HAHis-Rasd1[T38N] and HAHisRasd1[ΔCAAX] were significantly less than that of HAHis-Rasd1
and HAHis-Rasd1[A178V] (compare panel c, lanes I and II with lanes III-V).
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mutations will interfere with their ability to interact with
Ear2, we conducted co-immunoprecipitation analyses. The
immunoblotting results showed that significantly less
Rasd1[G81A], Rasd1[T38N] and Rasd1[ΔCAAX] were
co-precipitated with immobilized GST-Ear2 when com-
pared to wild type Rasd1 and Rasd1[A178V] (compare
Figure 6D, panel a, lanes I and II with lanes III-V).
Similarly, noticeably less GST-Ear2 co-precipitated with
immobilized Rasd1[G81A], Rasd1[T38N] and Rasd1
[ΔCAAX] compared to immobilized wild type Rasd1 and
Rasd1[A178V] (compare Figure 6D, panel c, lanes I and II
with lanes III-V). These results suggest that mutation of
amino acid 81, 38 and deletion of the CAAX box of Rasd1
affects the ability of Rasd1to interact with Ear2.
Discussion
In our present study, we identified Ear2 as a direct
interacting target of Rasd1. The interaction between
Ear2 and Rasd1 was confirmed in vitro and in living
cells. Ear2 interacts with Rasd1 via its ligand binding
domain. In addition, we demonstrated that Rasd1 is able
to alleviate both retinoic acid-dependent and indepen-
dent Ear2-mediated transcriptional repression of renin
promoter activity. Furthermore, we showed that the
Rasd1 mutants, Rasd1[G81A], Rasd1[T38N] and Rasd1
[ΔCAAX], which have reduced physical interaction with
Ear2, are ineffective in counteracting repression of renin
transcription by Ear2. Our current data suggests that
Rasd1 may facilitate the translocation of Ear2 from the
nucleus to the cytoplasm. Alternatively, Rasd1 may bind
to Ear2 and render it inactive in the transrepression of
renin promoter. Further experiments are required to
delineate the detailed mechanism by which Rasd1 coun-
teracts repression of renin transcription by Ear2.
Ear2 is involved in the negative regulation of renin
gene transcription [13]. Renin is the rate-limiting
enzyme in the renin-angiotensin enzymatic cascade
which leads to the production of the bioactive product
Angiotensin-II [2,3]. However, despite the efforts aimed
at characterizing the renin enhancer, its functional rele-
vance in vivo has yet to be determined. In our study, we
showed that Rasd1 interacts with Ear2, and this finding
prompted us further to investigate the role of Rasd1 on
Ear2-mediated renin transcription. Interestingly, we
found that Rasd1 alleviated Ear2-repressed renin tran-
scription in a dosage-dependent manner and that this
novel function of Rasd1 required a specific interaction
between Rasd1 and the ligand binding domain of Ear2.
The renin transcriptional enhancer contains both posi-
tive and negative regulatory elements [9-12]. Among
them is an unusual RARE with TGACC tandem repeats
separated by 10 nucleotides (TGACCT-DR10-TGACCT),
which is required for both retinoic acid-mediated and
retinoic acid-independent activity of the enhancer [9].
Ear2 has been shown to mediate negative regulation of
renin transcription by competing with RAR/RXR for its
binding to RARE [9,13]. Our experiments showed that
Rasd1 is able to relieve Ear2-mediated transcriptional
repression of renin via direct interaction with Ear2 both
in the presence or absence of retinoic acid. It is possible
that Rasd1 acts by binding directly to Ear2, sequestering
Ear2 from the nucleus to the cytoplasm, and removing
the inhibitory effect of Ear2 by allowing other stimulatory
factors to bind to the renin enhancer. Rasd1 contains a
bipartite nuclear localization [36], and has been shown to
be present in both nucleus and cytosol [36]. Our immu-
nofluorescence and confocal studies showed that a signif-
icant amount of Rasd1 is localized in the nuclei.
Interestingly, when Rasd1 was co-transfected with Ear2,
it resulted in the movement of a significant amount of
Ear2 from the nucleus into the cytosol. This suggests that
Rasd1 may play a role in regulating Ear2 nucleus-cytosol
distribution.
Rasd1 belongs to the RAS superfamily. Members of
the RAS superfamily are highly conserved in sequence
and show high degrees of homology across species.
Similar to other members of the RAS superfamily,
Rasd1 possesses five highly conserved motifs for GTP
binding and hydrolysis (G1-G5), an effector loop that
mediates protein-protein interactions, and a C-terminus
CAAX box that serves as a consensus site for the iso-
prenylation required for membrane localization [34].
Despite extensive similarities to members of the Ras
family, Rasd1 also possesses several differences, includ-
ing an extended carboxyl terminus variable cationic
domain and a high basic net isoelectric point [42].
These differences indicate that Rasd1 may play diverse
biological roles that have yet to be discovered. This
study demonstrates that Rasd1 serves a novel role in the
regulation of Ear2-mediated renin transcription. In view
of the highly conserved sequence and function of mem-
bers of the RAS superfamily, we generated several Rasd1
mutants in an attempt to elucidate the molecular basis
of the alleviation of Ear2-mediated repression of renin
transcription by Rasd1. As expected, Rasd1[A178V], a
constitutively active mutant of Rasd1, was able to allevi-
ate Ear2-mediated transcriptional repression of renin
promoter activity. In contrast, Rasd1[G81A], Rasd1
[T38N] and Rasd1[ΔCAAX] did not alleviate Ear2-
mediated repression of renin transcription. This suggests
that GTPase activity, GDP-GTP exchange by GEFs, iso-
prenylation and possibly, the targeting of Rasd1 to the
cell membrane are all involved in this function. Mutant
H-RAS[S17N] inhibits Ras dependent pathways and has
been shown to have a much higher affinity for GDP
than GTP [40]. As expected, the corresponding Rasd1
[T38N] mutant was inactive with respect to the upregu-
lation of renin transcription. Similarly, the CAAX
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box-deficient mutant, Rasd1[ΔCAAX], was unable to
upregulate renin transcription, thus suggesting that
isoprenylation and membrane colocalization of Rasd1 is
necessary. Likewise, mutant Rasd1[G81A], which binds
with reduced affinity to GAPs and possesses attenuated
GTPase activity [38], did not alleviate Ear2-mediated
repression of renin transcription. We propose a few
plausible explanations for this observation. The binding
of Rasd1 to Ear2 and the subsequent translocation and
retention of Ear2 in the cytosol by Rasd1 may require
the GTP hydrolysis activity of Rasd1. Thus, Rasd1
[G81A], with reduced GTPase activity, does not effec-
tively bind to Ear2 and translocate it out of the nucleus
to remove the repression of Ear2 on the renin promoter.
Alternatively, the lack of functional activity of Rasd1
[G81A] may be due to a reduced affinity of Rasd1
[G81A] for Ear2. In H-RAS, the G60A mutation per-
turbs GTP-induced conformational change and
abolishes biological activity [43]. In another example, a
corresponding mutant of EF-Tu, EF-Tu[G83A], has
increased GTPase activity and a reduced binding affinity
for aa-tRNA [44].
When we conducted interaction studies, it was discov-
ered that Rasd1[G81A], Rasd1[T38N], Rasd1[ΔCAAX]
had visibly weaker interactions with Ear2 compared to
wild type Rasd1 and Rasd1[A178V]. Immunofluores-
cence and confocal studies further show that Rasd1
[G81A], Rasd1[T38N] and Rasd1[ΔCAAX] were ineffec-
tive in translocating and retaining Ear2 in the cytoplasm.
It is also interesting to note that while wild type Rasd1,
Rasd1[A178V] and Rasd1[T38N] were present in both
the nucleus and cytoplasm, Rasd1[G81A] and Rasd1
[ΔCAAX] were localized mainly in the nucleus, suggest-
ing that GTPase activity and isoprenylation of Rasd1
affects Rasd1 nuclear-cytoplasmic distribution. Taken
together, our data implies that GTPase activity, GDP-
GTP exchange and isoprenylation and membrane locali-
zation of Rasd1 is required for its functional activity in
the mediation of Ear2-repressed renin transcription.
Rasd1 mutants that possess these defects were rendered
ineffective in the alleviation of Ear2-repressed renin
transcription, possibly due to a weakened interaction
with Ear2 and/or a reduced effectiveness in the translo-
cation of Ear2 from the nucleus to the cytoplasm.
Many physiological functions, such as blood pressure,
exhibit endogenous rhythmic variability corresponding
to a day-night cycle of close to 24 hours and driven by
the circadian system, which consists of central oscilla-
tors in the SCN and peripheral oscillators in organs like
the heart, pancreas, kidneys and liver [45-47]. The
expression of Rasd1 in the SCN exhibits a circadian
rhythm [29]. This leads us to speculate about the rele-
vance of Rasd1’s involvement in the regulation of Ear2-
mediated renin transcription. We postulate that Rasd1
might be a player in the regulation of the daily circadian
pattern of blood pressure through its interaction with
Ear2 and consequent effect on renin transcription. Inter-
estingly, Ear2-/- mice displayed reduced efficiency to
photic and feeding time cues entrainment [25]. Ear2 is
also required for the normal rhythmic expression of
Per1 in the forebrain [25,48]. Might Rasd1 and Ear2,
together with other clock genes, work in a currently
unknown, complex interacting cascade to affect the cir-
cadian control of the renin-angiotensin pathway?
There is substantial evidence supporting the existence
of a complete and functionally competent renin-angio-
tensin system in the brain [3,49-51]. In addition to the
classical roles of peripheral angiotensins, various studies
have shown that central angiotensins are also involved
in less conventional functions, such as sexual behavior
[52,53], stress [54-56], and learning and memory [52].
There are also studies that show that the renin-angio-
tensin system is involved in neurological disorders,
including Alzheimer’s [57-60] and Parkinson’s [60,61]
disease. Our identification of this novel regulatory
mechanism of the renin-angiotensin system opens
exciting possibilities for future research and will be of
considerable interest for clinical application. The renin-
angiotensin system, classically known for its involvement
in the regulation of blood pressure, has been a target in
the development of drugs for the treatment of hyperten-
sion. Hypertension is in turn a potent risk factor for car-
diovascular diseases, such as stroke, atherosclerosis, and
heart attacks [62-64]. Clinically, inhibitors of the renin-
angiotensin system are observed to be effective antihy-
pertensive treatments [65-67]. Targeting the brain
renin-angiotensin system may also be a viable option for
the treatment of mood disorders, cognitive dysfunctions
and even neurodegenerative diseases. Obtaining a better
understanding of the regulation of the renin-angiotensin
system may eventually lead to the production of more
effective drugs.
Conclusions
We conclude that Rasd1 and Ear2 interact physically
and functionally. This interaction counteracts the
repression of renin transcription by Ear2. Since Ear2 is
also known to play an important role in brain develop-
ment and circadian control, it remains to be determined
how the interplay between these two proteins regulates
spatial-temporal developmental and physiological pro-
cesses. The results of this study could provide mechanis-
tic insights into Rasd1’s ability to modulate these
processes through its interaction with Ear2.
Methods
Yeast two-hybrid screening- All vectors, yeast strains,
reagents and methods were derived from the
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MATCHMAKER Two-Hybrid System 3 (Clontech, Palo
Alto, CA, USA). PCR-generated 843bp full length
mouse Rasd1 cDNA was inserted into NdeI and EcoRI
digested vector pGBKT7 as an in-frame fusion with the
DNA binding domain of GAL4 at its 3’ end, and the
resulting plasmid was designated pGBKT7-Rasd1. The
correct insertion of Rasd1 was confirmed by restriction
analysis and verified by sequencing. pGBKT7 carries the
yeast nutritional selection marker TRP1. Library screen-
ing was performed using Rasd1-Gal4 DNA binding
domain fusion protein expressed from pGBKT7-Rasd1
as the bait. Absence of autonomous activation of
reported genes in yeast was verified by bait before
library screening. Mouse brain MATCHMAKER cDNA
library culture (Clontech, Palo Alto, CA, USA) was used
as prey. The library was cloned into pACT2 vector that
encodes for the GAL4 transactivation domain and LEU2
as the yeast nutritional selection marker. Yeast strains
used were AH109 and Y187. AH109 contains two nutri-
tional reported genes for adenine and histidine. Yeast
transformations were performed using high-efficiency
lithium acetate/poly-ethylene glycol method [68]. Yeast
AH109 was transformed with pGBKT7-Rasd1 and nutri-
tionally selected on synthetic dropout (SD)-trp plates.
Mouse brain cDNA library cloned in pACT2 was then
co-transformed into yeast AH109 that contained
pGBKT7-Rasd1 and plated on SD-trp-leu medium to
nutritionally select for the presence of both proteins.
Putatively positive colonies were selected on SD-ade-his-
trp-leu plates and assayed for b-galactosidase activity by
use of 5-bromo-4-chloro-3-indolyl-b-D-galactopyrano-
side (X-gal) as a substrate. Secondary screens were per-
formed in a similar manner to minimize false positives.
Positive colonies were subcultured and grown to satura-
tion in SD-leu medium to expel the bait plasmid.
Library plasmids from positive interacting colonies were
recovered and sorted into groups according to PCR pro-
duct sizes with primers MATCHMAKER 5’ AD LD-
Insert screening amplimer and 3’ AD LD-Insert screen-
ing amplimer and restriction digestion pattern with
HpaII. The clones were then sequenced using GAL4
activation domain sequencing primer. BLAST searches
(National Centre for Biotechnology Information,
NCBI) were performed to identify these clones. The
specificity of protein-protein interaction was further
tested by yeast mating according to manufacturer’s
protocol. Y187 was transformed with either pGBKT7-
Rasd1 or pGBKT7 vector, and nutritionally selected in
medium lacking tryptophan. AH109 was transformed
with either pACT2-Ear2 or pACT2 vector alone and
grown in medium lacking leucine. To verify the puta-
tive positive clones, the transformed yeast strain
AH109(MATa) were then mated with Y187(MATa)
and grown in medium lacking tryptophan and leucine.
The cells were then replica plated on SD-ade-his-trp-
leu and re-assayed for b-galactosidase activity.
Plasmids- The pHisHA-Rasd1 construct was generated
by cloning the 843 bp coding region of Rasd1 into KpnI
and EcoRI digested pcDNA4/HisMax©B (Stratagene)
vector. Rasd1 was tagged in frame with the 5’ polyHis
tag and Xpress epitope. In addition, a hemagglutinin
(HA) tag was added in frame with the coding region of
Rasd1 at its 3’ terminal using polymerase chain reaction
(PCR). Rasd1[ΔCAAX] was also cloned into KpnI and
EcoRI digested pcDNA4/HisMax©B. Site-directed muta-
genesis based on overlap extension PCR [69] using two
common flanking primers along with individual overlap-
ping mutagenic primers was used to generate the Rasd1
mutant constructs A178V, G81A and T38N. The result-
ing PCR products were cloned into KpnI and EcoRI
digested pcDNA4/HisMax©B. pGST-Ear2 construct
was generated by cloning the 1173bp Ear2 coding
region into pxJGST vector, tagged in frame with a 5’
glutathione-S-transferase (GST) tag with the inFusion
cloning kit (Clontech), using NotI restriction site. GST-
Ear2 truncated constructs carrying DNA sequences cor-
responding to amino acids 1-193, 1-130, 1-53, 54-390,
131-390 and 194-390 of Ear2 were also cloned into NotI
digested pxJGST vector. pxJGST vector was derived
from pxJ-FLAG-S vector [70]. p4.1-Luc construct was
generated by cloning the 4.1kb renin promoter into
NheI and HindIII digested pGL3-basic vector (Promega).
Rasd1 shRNA knockdown plasmid construct was gener-
ated by annealing oligonucleotides targeted at the open
reading frame of Rasd1 and inserting the annealed oligo-
nucleotides into BglII and HindIII digested pSUPER.
puro (Oligoengine) vector. Control shRNA was gener-
ated by inserting randomly jumbled sequences of the
Rasd1 shRNA oligonucleotide sequences into BglII and
HindIII digested pSUPER.puro. All clones were checked
by restriction analysis and verified by sequencing.
Cell culture and Transfection- COS-7 cells (American
Type Culture Collection, ATCC CRL-1651) were main-
tained in RPMI1640 (HyClone). As4.1 cells (ATCC
CRL-2193) were maintained in DMEM (ATCC). Neu-
ro2a cells were maintained in MEM (Hyclone).
HEK293T cells were maintained in DMEM (Hyclone).
All media was supplemented with 10% FBS, penicillin
(100 U/mL) and streptomycin (100 mg/mL). Cells
(3.0-3.5 × 105) were cultured in each well of 6-well cul-
ture plates for 24 hours before transfection. For pull-
down assays, confocal studies and experiments that
measure endogenous renin levels, cells were transfected
with 2.5 μg of pGST-Ear2 per well. In co-transfection
experiments, pHisHA-Rasd1 (3.5 μg) was transfected
together with pGST-Ear2 (2.0 μg). For luciferase assays,
cells were transfected with p4.1-Luc or pGL3-basic
(2.0 μg), pGST-Ear2 (0.5- 1.5 μg), pHisHA-Rasd1
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(0.1- 1.5 μg), pSV-b-gal (0.5 μg) in the combinations as
indicated in the figure legends. Total amount of trans-
fected DNA in all transfections were held constant with
the appropriate amounts of respective empty vector
added to the plasmid mix. shRNA knockdown experi-
ments were performed by transfecting Rasd1 shRNA or
non-targeting control shRNA (2 μg/ml). Selection with
puromycin (2 μg/ml) and dexamethasone (100 nM)
treatment was carried out 24 hours post transfection,
and cells were harvested 48 hours post transfection.
Knockdown efficiency was determined by semi-quantita-
tive RT-PCR and Western blotting. Quantification of
immunoblots was measured using the GS-800 calibrated
densitometer (Bio-Rad). Transfection was carried out
with DNA (μg) to Lipofectamine 2000 (μl) (Invitrogen)
ratio of 1:2, according to manufacturer’s instructions.
Protein binding assays- In GST pulldown assays, COS-
7 cells were transfected separately with pGST-Ear2 and
pHisHA-Rasd1. Cells were harvested 40 to 48 hours
after transfection and lysed with lysis buffer (1% Triton-
X 100, 15% Glycerol, 1 mM phenylmethylsulphonyl
fluoride, 150 mM NaCl, 100 mM Tris, pH 7.4, protease
inhibitor (Roche)) for 20 minutes to 1 hour, on a rotat-
ing platform, at 4°C. For cell lysis, 100 μl of lysis buffer
was added into each well of a 6-well plate. Crude cell
lysate was cleared by centrifugation at 13,000 rpm, 4°C
for 20 minutes. GST fusion proteins were immobilized
on magnetic glutathione (GSH)-linked beads (Promega)
by incubating 200 μl of the respective crude cell lysate
with GSH-linked beads on a rotating platform for 30
minutes at room temperature. The beads were then
washed 3 times with binding/washing buffer (Promega)
and resuspended in 40 μl of the same binding/washing
buffer. Cellular lysate (100 μl) from pHA-Rasd1 trans-
fected cells was then incubated with the GST-Ear2 pro-
teins immobilized on magnetic GSH-linked beads on a
rotating platform for 1 hour, at room temperature, with
1% bovine serum albumin (BSA) as the blocking
reagent. After incubation, the beads were vortexed once,
and then washed five times with binding/washing buffer,
and bound proteins were eluted from the GSH-linked
beads by heating in Laemmli buffer at 95°C for
10 minutes.
In co-precipitation assays, COS-7 cells were co-trans-
fected with pHisHA-Rasd1 and pGST-Ear2. Cells were
harvested as described above. GST fusion proteins were
immobilized on magnetic GSH-linked beads by incubat-
ing 200 μl of the cleared crude cell lysate with 30 μl of
GSH-linked beads, with 1% BSA, on a rotating platform
for 1 hour at room temperature. After incubation, the
beads were washed four times with binding/washing
buffer, and bound proteins were eluted from the GSH-
linked beads by heating in Laemmli buffer at 95°C for
10 minutes.
Co-immunoprecipitations were performed by first
pre-clearing 200 μl of crude cell lysate with 4 μg of
mouse monoclonal IgG1 antibody (anti-c-Myc antibody,
Santa Cruz), for 1 hour, on ice. The cell lysate was then
incubated with 20 μl of protein G agarose resin beads
(Invitrogen), for 30 minutes at 4°C on a rotating plat-
form, followed by centrifugation at 14,000 × g for 10
minutes at 4°C. The supernatant was incubated with 4
μg of anti-GST antibody overnight, followed by 20 μl of
resin beads for 1.5 hours, both on a rotating platform at
4°C. The resin was recovered after centrifugation at
13,000 rpm for 10 minutes at 4°C, washed once with
PBS buffer and bound proteins were finally eluted from
the resin beads by heating in Laemmli buffer at 95°C for
10 minutes.
Immunoprecipitation of endogenous Rasd1-Ear2 com-
plexes was performed using crude lysate from untrans-
fected HEK293T cells, as well as mouse brain crude
lysate. Procedure was similar to co-immunoprecipitation
protocol except that the crude cell lysate was pre-
cleared with 80 μl of protein-G agarose resin beads for
30 minutes at 4°C. Goat polyclonal IgG anti-Ear2
antibody (Santa Cruz) was used to carry out immuno-
precipitation, and a non-relevant goat polyclonal IgG
anti-Tdg antibody (Santa Cruz) served as negative con-
trol. Immobilization of HisHA-Rasd1 was carried out
using Ni-NTA Magnetic agarose beads (Qiagen) accord-
ing to manufacturer’s protocol. The Ni-NTA magnetic
beads target the 5’-polyHis tag present on our HisHA-
Rasd1 construct.
Proteins were analyzed using Western blots. Protein
samples mixed with 1X Laemmli buffer were heated at
95°C for 10 minutes, separated by 10% SDS-PAGE,
then transferred to polyvinylidene fluoride (PVDF)
membranes (Bio-Rad, CA, USA). Blots were blocked in
5% non-fat milk, overnight at 4°C. Primary antibodies
used included anti-GST mouse monoclonal IgG1
(1:5000) (Santa Cruz), anti-HA mouse monoclonal
IgG2a (1:250) (Santa Cruz), anti-Ear2 goat polyclonal
IgG (1:250) (Santa Cruz) and goat polyclonal anti-
Rasd1 (1:1000) (Abcam). Secondary antibodies used
included sheep anti-mouse horseradish peroxidase
(HRP)-linked IgG (1:5000) (Amersham, GE Healthcare,
UK) and rabbit anti-goat HRP-linked IgG (Abcam).
Detection was performed with Western blot ECL kit
detection reagents (Amersham, GE Healthcare, UK).
All washes in between incubations are with TBST
(0.1% Tween-20), for three times of 10 minutes each,
at room temperature.
Immunofluorescence staining- Transfected COS-7 cells
were used for indirect immunofluorescence staining as
described [36]. HisHA-Rasd1 was detected with anti-HA
antibody and visualized with goat anti-mouse IgG Alex-
aFluor 568 (Invitrogen). GST-Ear2 was detected and
Tan et al. BMC Molecular Biology 2011, 12:4
http://www.biomedcentral.com/1471-2199/12/4
Page 14 of 17
visualized with anti-GST AlexaFluor 488 (Santa Cruz)
by confocal microscopy (Zeiss). Nuclei were stained by
4’,6-diamidino-2-phenylindole (Sigma).
Luciferase reporter assay- Luciferase assays were per-
formed using a Luciferase Assay System (Promega) kit
according to manufacturer’s protocol. COS-7, Neuro2a
or As4.1 cells were co-transfected with pSV-b-Galactosi-
dase, p4.1-Luc and relevant amounts of Ear2 and Rasd1
constructs. Total DNA concentration was held constant
with respective carrier plasmid DNA. Cells were treated
with 1 μM all-trans retinoic acid at 24 hours post trans-
fection where applicable. Cells were harvested in 1X
reporter lysis buffer (Promega) at 48 hours post trans-
fection. The firefly luciferase activity was measured by a
20/20n Luminometer (Turner Biosystems). b-galactosi-
dase (b-gal) levels were measured using b-Galactosidase
Enzyme Assay System (Promega) according to manufac-
turer’s protocol. Luciferase activity was normalized
against b-gal activity. Basal activity of promoterless
enhancerless pGL3-basic was set to 100. Relative lucifer-
ase activities for all constructs were obtained from divid-
ing normalized values against values obtained from
promoter-less pGL3-basic. At least 3 sets of triplicates
were conducted for each experiment. For all luciferase
reporter assays, statistical analyses were performed using
ANOVA or unpaired t-tests. Error bars shown are stan-
dard deviations.
Real-time RT-PCR- Total RNA was harvested from
As4.1 cells 24 hours or 48 hours post transfection with
Trizol reagent (Invitrogen) according to the manufac-
turer’s protocol. The reverse transcription reaction was
performed using iScript cDNA synthesis kit (Bio-Rad).
Real-time PCR was performed with iTaq SYBR green
supermix (Bio-Rad). The cycling conditions are 95°C
for 15 seconds, 60°C for 30 seconds (for renin and
G3PDH) or 66.5°C for 30 seconds (for Rasd1), 72°C for
40 seconds, 40 cycles. The number of PCR cycles for
semi-quantitative real time RT-PCR was optimized to
ensure that the reactions were in the linear range of
amplification (G3PDH for 15 cycles, renin for 19 cycles
and Rasd1 for 21 cycles). The amount of transcribed
cDNA was normalized to G3PDH expression with the
7500 Real-time PCR system (Applied Biosystem).
Three independent experiments were performed in
duplicate.
Refer to Additional file 1 for oligonucleotides used in
this study.
Additional material
Additional File 1: List of oligonucleotides used for cloning and
sequencing. Tabulated data of oligonucleotides used in the experiments
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